TriangleHEALTH PROFESSIONAL · SOURCE READING
Chemotherapy and targeted therapy
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Recurrent Soft Tissue Sarcoma / Treatment Options for Recurrent Soft Tissue Sarcoma
Single-agent chemotherapy may be used with other single agents for disease recurrence.[11-16] Agents such as ifosfamide or gemcitabine may be used sequentially at the time of recurrence or progression.[13-15,17][Level of evidence C3] However, as none of these agents have been shown to increase overall survival (OS) in this setting, clinical trials are an appropriate option.
The U.S. Food and Drug Administration (FDA) has approved eribulin, trabectedin, and pazopanib for the treatment of soft tissue sarcomas after failure of a first-line chemotherapy regimen.
Continue within this section
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice